Today’s Watch List: CONSOL Energy Inc. (NYSE:CNX), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Penn West Petroleum Ltd. (NYSE:PWE), Halozyme Therapeutics, Inc.

CONSOL Energy Inc. (NYSE:CNX) said that, it is selling several mines and coal reserves to Coronado IV LLC. for $420 million. It says it will also suspend its dividend as it continues to deal with declining energy prices.

CONSOL Energy Inc. (NYSE:CNX) belongs to Basic Materials sector. Its net profit margin is -15.00% and weekly performance is -0.80%. On last trading day company shares ended up at $8.63. CONSOL Energy Inc. (NYSE:CNX) distance from 50-day simple moving average (SMA50) is 15.97%.

On 25 February, Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) announced its financial results for the fourth quarter and year ended December 31, 2015. For the full year 2015, Auryxia net U.S. product sales were $10.1 million, representing greater than 18,000 prescriptions.

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) shares advanced 10.44% in last trading session and ended the day at $4.02. KERX Gross Margin is 37.60% and its return on assets is -78.40%. Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) quarterly performance is -26.78%.

On 16 February, Penn West Petroleum Ltd. (NYSE:PWE) has reached agreements to settle a bevy of class-action lawsuits stemming from accounting. The settlement in the Canadian and U.S. cases will be fully funded by the company’s insurance, meaning its cash resources and financial position won’t take a hit.

Penn West Petroleum Ltd. (NYSE:PWE) belongs to Basic Materials sector. Its weekly performance is -7.72%. On last trading day company shares ended up at $0.93. Penn West Petroleum Ltd. (NYSE:PWE) distance from 50-day simple moving average (SMA50) is 17.03%.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported financial results for the fourth quarter and full year ended December 31, 2015, which included a fourth quarter increase in royalty revenue of 136 percent from the prior year period and net income of $4.3 million, or $0.03 per share, compared to a net loss in the fourth quarter of 2014 of $5.3 million, or $0.04 per share. For the full year, total revenue increased 79 percent to $135.1 million compared to $75.3 million in the prior year.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares moved down -1.45% in last trading session and ended the day at $8.13. HALO Gross Margin is 76.10% and its return on assets is -25.50%. Halozyme Therapeutics, Inc. (NASDAQ:HALO) quarterly performance is -53.94%.

SINA Corporation (NASDAQ:SINA) will announce its unaudited financial results for the fourth quarter 2015 after the close of market on Wednesday, March 2, 2016. Following the announcement, SINA’s management team will host a conference call from 9:10 p.m. –9:50 p.m. Eastern Time on March 2, 2016 (or 10:10 a.m. — 10:50 a.m. Beijing Time on March 3, 2016) to present an overview of the Company’s financial performance and business operations.

On 29 February, SINA Corporation (NASDAQ:SINA) shares moved down -3.04% and was closed at $42.72. SINA EPS growth in last 5 year was -18.70%. SINA Corporation (NASDAQ:SINA) year to date (YTD) performance is -13.52%.

Leave a Reply

Your email address will not be published. Required fields are marked *